You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Circulating Diagnostic Markers of Infectious Disease

    SBC: PATHOVACS INCORPORATED            Topic: CBD18A001

    The focus of this STTR phase I component is on proof-of-concept studies demonstrating applicability of technical approaches for identificationof circulatory diagnostic markers for infectious disease. Therefore, the primary objective of this project is to determine feasibility of one suchtechnical approach called Proteomics-based Expression Library Screening (PELS), for identification of pathogen-d ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  2. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD RESEARCH CORPORATION            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  3. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  4. Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus

    SBC: EVRYS BIO LLC            Topic: CBD18A002

    In a pandemic or exposure to weaponized Marburg virus the morbidity, mortality and social unrest that will ensue before vaccines orMilitary operating on foreign soil as well as to the population of the US Homeland. Practically all threat agents of biological origin (except forcertain non-proteinaceous toxins, typically produced by marine organisms and fungi) have their structure and vital function ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  5. Virus-Like Particle Based pan-Marburgvirus Vaccine

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: CBD18A002

    Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  6. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  7. Compact Laser Drivers for Photoconductive Semicond

    SBC: SCIENTIFIC APPLICATIONS & RESEARCH ASSOCIATES, INC.            Topic: DTRA16A004

    For effective protection against radiated threats, it is important to understand not only the physics of the threats, but also to quantify the effects they have on mission-critical electrical systems. Radiated vulnerability and susceptibility testing requires delivery of high peak power and peak electric fields to distant targets. The most practical solution to simulate such environments on large ...

    STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  8. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point ofCare Applications

    SBC: GENECAPTURE, INC.            Topic: CBD15C001

    GeneCapture, Inc. is proposing to develop a rapid in vitro diagnostic prototype using our patented molecular-based CAPTURE (ConfirmActive Pathogens Through Unamplified RNA Expression) assay. Based on the results and experience gained in our Phase I STTR contractHDTRA1-16C-0061: Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications, we p ...

    STTR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense
  9. Development of powder bed printing (3DP) for rapid and flexible fabrication of energetic material payloads and munitions

    SBC: MAKEL ENGINEERING, INC.            Topic: DTRA16A001

    This program will demonstrate how additive manufacturing technologies can be used with reactive and high energy materials to create rapid and flexible fabrication of payload and munitions. Our primary approach to this problem will be to use powder bed binder printing techniques to print reactive structures. The anticipated feedstock will consist of composite particles containing all reactant spe ...

    STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
  10. Rapid Development of Weapon Payloads via Additive Manufacturing

    SBC: MATSYS INCORPORATED            Topic: DTRA16A001

    MATSYS proposes to adapt emerging additive manufacturing techniques (so-called 3-D Printing) for use with reactive structural materials and demonstrate this capability to rapidly fabricate reactive case. Our concept incorporates two major manufacturing steps: 3D printing of green compacts from pure Al or Al-based reactive powder blend; and Microwave (MW) sintering of green compacts into net-shaped ...

    STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
US Flag An Official Website of the United States Government